| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8062667 | NEXTWAVE | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2029
(4 years from now) | |
| US8465765 | NEXTWAVE | Orally effective methylphenidate extended release powder and aqueous suspension product |
Feb, 2031
(6 years from now) | |
| US8563033 | NEXTWAVE | Orally effective methylphenidate extended release powder and aqueous suspension product |
Feb, 2031
(6 years from now) | |
| US8956649 | NEXTWAVE | Orally effective methylphenidate extended release powder and aqueous suspension product |
Feb, 2031
(6 years from now) | |
| US9040083 | NEXTWAVE | Orally effective methylphenidate extended release powder and aqueous suspension product |
Feb, 2031
(6 years from now) | |
| US8287903 | NEXTWAVE | Orally effective methylphenidate extended release powder and aqueous suspension product |
Feb, 2031
(6 years from now) | |
| US8778390 | NEXTWAVE | Orally effective methylphenidate extended release powder and aqueous suspension product |
Feb, 2031
(6 years from now) | |
Quillivant Xr is owned by Nextwave.
Quillivant Xr contains Methylphenidate Hydrochloride.
Quillivant Xr has a total of 7 drug patents out of which 0 drug patents have expired.
Quillivant Xr was authorised for market use on 27 September, 2012.
Quillivant Xr is available in for suspension, extended release;oral dosage forms.
Quillivant Xr can be used as method of treating attention deficit hyperactivity disorder by administering the composition of claim 1, treating a patient having a condition susceptible to treatment with methylphenidate, such as adhd, by administering the formulation recited in claims 1 or 2, treatment of a patient by administering the formulation recited in claim 1 or claim 23.
The generics of Quillivant Xr are possible to be released after 15 February, 2031.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Sep 27, 2015 |
Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient
Market Authorisation Date: 27 September, 2012
Treatment: Treating a patient having a condition susceptible to treatment with methylphenidate, such as adhd, by administering the formulation recited in claims 1 or 2; Method of treating attention deficit hyper...
Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL
QUILLIVANT XR family patents
